1 – 10 of 52
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Occurrence and relative risks for non-vertebral fractures in patients with ankylosing spondylitis compared with the general population : a register-based study from Sweden
(
- Contribution to journal › Article
- 2022
-
Mark
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
(
- Contribution to journal › Article
-
Mark
Comment on : Incidence of extra-articular manifestations in AS, PsA and undifferentiated SpA: Results from a national register-based cohort study. Reply
(
- Contribution to journal › Letter
-
Mark
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : Results from four Nordic countries
(
- Contribution to journal › Article
-
Mark
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis : Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
(
- Contribution to journal › Article
-
Mark
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration
(
- Contribution to journal › Article
- 2021
-
Mark
Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population : a nationwide register-based cohort study 2002–2017
(
- Contribution to journal › Article
-
Mark
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care : Does the choice of biological therapy matter?
(
- Contribution to journal › Article
-
Mark
Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis : Results from a national register-based cohort study
(
- Contribution to journal › Article
-
Mark
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine
(
- Contribution to journal › Article